Literature DB >> 18188713

Functional characterization of the GDEP promoter and three enhancer elements in retinoblastoma and prostate cell lines.

D S Cross1, J K Burmester.   

Abstract

GDEP (gene differentially expressed in prostate cancer aka. PCAN1), a newly discovered gene with remarkable tissue specificity, is a promising candidate for regulatory analysis because it exhibits a high level of expression that is limited to two tissues, the retina and the prostate. As these two tissues have different origins and disparate functions it is likely that the regulatory mechanisms responsible for expression are not shared in their entirety. In addition, both the retina and prostate are prime targets for gene therapy. To date there have been no functional studies of the GDEP promoter. Therefore to understand tissue-specific expression of GDEP we constructed promoter expression constructs. To further characterize functional regulatory regions within the GDEP gene, we investigated potential regulatory components for tissue-specific expression in the 40 kb intron of this gene. We have identified a 1.5 kb prostate-specific promoter from the proximal region of the GDEP gene. A smaller 0.5 kb promoter exhibited minimal activity in the retinoblastoma cell line Y79, but not in the prostate cells tested. In addition we have investigated three enhancer elements located in the 40 kb intron of the GDEP gene. We identified two enhancer elements that increase reporter gene expression in prostate cell line LNCaP and one additional enhancer element that increases expression in the Y79 cell line approximately 8-fold making it a strong retinal-specific enhancer.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18188713     DOI: 10.1007/s12032-007-0038-4

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  29 in total

1.  A novel method for the determination of basal gene expression of tissue-specific promoters: an analysis of prostate-specific promoters.

Authors:  H G van der Poel; J McCadden; G W Verhaegh; M Kruszewski; F Ferrer; J A Schalken; M Carducci; R Rodriguez
Journal:  Cancer Gene Ther       Date:  2001-12       Impact factor: 5.987

2.  Cancer gene therapy: combination with radiation therapy and the role of bystander cell killing in the anti-tumor effect.

Authors:  Katalin Lumniczky; Géza Sáfrány
Journal:  Pathol Oncol Res       Date:  2006-06-24       Impact factor: 3.201

3.  Highly specific expression of luciferase gene in lungs of naïve nude mice directed by prostate-specific antigen promoter.

Authors:  Hong-Wei Li; Jinzhong Li; Gregory A Helm; Dongfeng Pan
Journal:  Biochem Biophys Res Commun       Date:  2005-09-09       Impact factor: 3.575

4.  Identification of a gene frequently mutated in prostate tumors.

Authors:  D J Reding; K Q Zhang; S A Salzman; J V Thomalla; R E Riepe; B K Suarez; W J Catalona; J K Burmester
Journal:  Med Oncol       Date:  2001       Impact factor: 3.064

5.  Clinical experience with gene therapy for the treatment of prostate cancer.

Authors:  Matthew A Stanizzi; Simon J Hall
Journal:  Rev Urol       Date:  2007

6.  GDEP, a new gene differentially expressed in normal prostate and prostate cancer.

Authors:  P Olsson; T K Bera; M Essand; V Kumar; P Duray; J Vincent; B Lee; I Pastan
Journal:  Prostate       Date:  2001-09-15       Impact factor: 4.104

7.  Cloning and characterization of the prostate-specific membrane antigen promoter.

Authors:  D Good; P Schwarzenberger; J A Eastham; R E Rhoads; J D Hunt; M Collins; M Batzer; C Theodossiou; J K Kolls; S R Grimes
Journal:  J Cell Biochem       Date:  1999-09-01       Impact factor: 4.429

8.  Elements regulating the transcription of human interstitial retinoid-binding protein (IRBP) gene in cultured retinoblastoma cells.

Authors:  S L Fong; W B Fong
Journal:  Curr Eye Res       Date:  1999-04       Impact factor: 2.424

9.  Novel prostate-specific promoter derived from PSA and PSMA enhancers.

Authors:  Sang-Jin Lee; Hong-Sup Kim; Rong Yu; KangRyul Lee; Thomas A Gardner; Chaeyong Jung; Meei-Huey Jeng; Fan Yeung; Liang Cheng; Chinghai Kao
Journal:  Mol Ther       Date:  2002-09       Impact factor: 11.454

10.  A novel TARP-promoter-based adenovirus against hormone-dependent and hormone-refractory prostate cancer.

Authors:  Wing-Shing Cheng; Robert Kraaij; Berith Nilsson; Laura van der Weel; Corrina M A de Ridder; Thomas H Tötterman; Magnus Essand
Journal:  Mol Ther       Date:  2004-08       Impact factor: 11.454

View more
  4 in total

Review 1.  A review of therapeutic prospects of non-viral gene therapy in the retinal pigment epithelium.

Authors:  Adarsha Koirala; Shannon M Conley; Muna I Naash
Journal:  Biomaterials       Date:  2013-06-22       Impact factor: 12.479

Review 2.  Nanoparticle-based technologies for retinal gene therapy.

Authors:  Jeffrey Adijanto; Muna I Naash
Journal:  Eur J Pharm Biopharm       Date:  2015-01-12       Impact factor: 5.571

3.  A kernel-based integration of genome-wide data for clinical decision support.

Authors:  Anneleen Daemen; Olivier Gevaert; Fabian Ojeda; Annelies Debucquoy; Johan Ak Suykens; Christine Sempoux; Jean-Pascal Machiels; Karin Haustermans; Bart De Moor
Journal:  Genome Med       Date:  2009-04-03       Impact factor: 11.117

4.  The long noncoding RNA landscape of neuroendocrine prostate cancer and its clinical implications.

Authors:  Varune Rohan Ramnarine; Mohammed Alshalalfa; Fan Mo; Noushin Nabavi; Nicholas Erho; Mandeep Takhar; Robert Shukin; Sonal Brahmbhatt; Alexander Gawronski; Maxim Kobelev; Mannan Nouri; Dong Lin; Harrison Tsai; Tamara L Lotan; R Jefferey Karnes; Mark A Rubin; Amina Zoubeidi; Martin E Gleave; Cenk Sahinalp; Alexander W Wyatt; Stanislav V Volik; Himisha Beltran; Elai Davicioni; Yuzhuo Wang; Colin C Collins
Journal:  Gigascience       Date:  2018-06-01       Impact factor: 6.524

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.